1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 13,680 | 13,760 | 20:34 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| DEVYSER DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 15.08. | Devyser im zweiten Quartal 2025: Umsatz steigt um 27 % bei Rückkehr in die Gewinnzone | 1 | Investing.com Deutsch | ||
| 15.08. | Devyser Q2 2025 presentation: Revenue jumps 27% as profitability returns | 3 | Investing.com | ||
| 22.07. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period April to June 2025 | 119 | GlobeNewswire (Europe) | "A positive operating result was recorded in the second quarter. The effects of the cost-cutting program initiated at the beginning of the year can already be seen in both current costs and in the cost... ► Artikel lesen | |
| 30.06. | Devyser Diagnostics AB: Devyser launches Genomic Blood Typing assay: All blood groups, one simple test | 127 | GlobeNewswire (Europe) | Devyser today announced the global launch of Devyser Genomic Blood Typing, a next-generation sequencing (NGS)-based solution that redefines molecular blood group research. Developed exclusively, this... ► Artikel lesen | |
| 29.04. | Devyser Q1 2025 slides reveal mixed results with 8% growth, EBIT challenges | 1 | Investing.com | ||
| 29.04. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period January to March 2025 | 378 | GlobeNewswire (Europe) | "A quarter has passed since I took over as acting CEO and it has been an eventful first few months. Despite the turbulent environment, marked by geopolitical uncertainty, we are able to report our second... ► Artikel lesen | |
| 14.04. | Devyser Diagnostics AB: Jan Wahlström new CEO for Devyser | 216 | GlobeNewswire (Europe) | Devyser's board has appointed Jan Wahlström as new CEO, effective August 4.Jan Wahlström has a long background in leading and developing companies in the Health Care and Life Science areas internationally.... ► Artikel lesen | |
| 19.02. | Devyser Diagnostics AB: Devyser secures a major SEK 16.8M tender in Italy with 30% growth | 241 | GlobeNewswire (Europe) | Devyser a leading provider of genetic testing solutions, has been awarded a significant tender for the supply of its comprehensive next-generation sequencing (NGS) tests for critical genetic markers.... ► Artikel lesen | |
| 13.02. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes year-end report for January to December 2024 | 372 | GlobeNewswire (Europe) | "Net sales increased during the fourth quarter by 41.5 percent to SEK 64.2 million, compared with the corresponding quarter of 2023. The growth and strong performance are a result of robust development... ► Artikel lesen | |
| 28.01. | Devyser Diagnostics AB: Devyser wins tender in Italy for its cystic fibrosis NGS test worth up to 5.4 million SEK | 200 | GlobeNewswire (Europe) | Devyser has secured a tender for its cystic fibrosis NGS test, Devyser CFTR. The tender with Policlinico di Bari is valid for five years with an estimated total order value up to 5.4 million SEK
"This... ► Artikel lesen | |
| 16.01. | Devyser Diagnostics AB: Devyser publishes preliminary result for Q4 2024 | 718 | GlobeNewswire (Europe) | In light of this morning's communication that Fredrik Alpsten is leaving his position as CEO of Devyser and to avoid speculation, Devyser is releasing a summary of the year-end report for 2024 before... ► Artikel lesen | |
| 30.10.24 | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period July to September 2024 | 151 | GlobeNewswire (Europe) | "It is very gratifying to see the impact that we are having in the field of diagnostics. I have just returned from the ASHI event, a major transplantation conference in the US, and it is clear that... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDTRONIC | 79,69 | -0,56 % | Medtronic plc: Medtronic initiates global pivotal study of cardiac pacing in a new patient population | Study to evaluate whether a new approach to pacing the heart can improve the lives of patients with heart failure with preserved ejection fraction (HFpEF) who have... ► Artikel lesen | |
| HCA HEALTHCARE | 343,60 | -0,46 % | Aktie von HCA kann Vortagsniveau nicht halten (336,5673 €) | Im Minus liegt gegenwärtig die HCA-Aktie . Die Aktie kostete zuletzt 394,09 US-Dollar. Die HCA-Aktie verzeichnet derzeit einen Abschlag von 4,67 Prozent. Sie hat sich um 19,31 US-Dollar gegenüber dem... ► Artikel lesen | |
| LANTHEUS | 44,890 | -0,47 % | Pre-market Movers: Myriad Genetics, LifeMD, Evolus, Lantheus Holdings, Astera Labs | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.15 A.M. ET).In the Green Myriad Genetics, Inc. (MYGN) is up over 30% at $5.04.
Astera... ► Artikel lesen | |
| ENVISTA | 18,400 | +2,79 % | Here's Why You Should Add NVST Stock to Your Portfolio Right Now | ||
| CAREDX | 11,660 | +1,26 % | CareDx Battles Reimbursement Uncertainty As Market Overlooks Long-Term Potential | ||
| SYNEOS HEALTH | - | - | Research Solutions, Inc.: Research Solutions Reports Preliminary Fourth Quarter and Fiscal Year 2025 Results | Expects Record Fiscal Year Revenue, Net Income, Adjusted EBITDA and Cash Flow
HENDERSON, Nev., Aug. 19, 2025 /PRNewswire/ -- Research Solutions, Inc. (NASDAQ:... ► Artikel lesen | |
| GT BIOPHARMA | 0,700 | +286,74 % | GT Biopharma, Inc.: GT Biopharma Reports Second Quarter 2025 Financial Results | GTB-3650 TriKE® Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2's formal safety review, it has advanced into Cohort 3 and... ► Artikel lesen | |
| CARMAT | 0,085 | +1,19 % | XFRA CXT: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| CHEMOMETEC | 82,25 | +0,55 % | Chemometec A/S: Annual Report 2024/25 - Growing revenue and EBITDA | ANNOUNCEMENT NO. 292 11 September 2025 Annual Report 2024/25 (1 July 2024 - 30 June 2025) Growing revenue and EBITDA ChemoMetec's revenue grew by 22% to DKK 495.6 million in 2024/25, and operating... ► Artikel lesen | |
| ARRAIL GROUP | 0,242 | -1,63 % | ARRAIL GROUP (06639): FORM OF PROXY FOR 2025 ANNUAL GENERAL MEETING | ||
| POLAREAN IMAGING | 0,002 | +200,00 % | AIM Market Roundup: Fiinu, T42 IOT, Polarean | ||
| PROMIMIC | 1,650 | +5,43 % | Curiteva & Promimic - Bonded by Innovation | HUNTSVILLE, ALABAMA / ACCESS Newswire / May 6, 2025 / Curiteva, a leader in 3D-printed Trabecular PEEK implant technology, is pleased to announce an expanded partnership with Promimic, pioneers in nanotechnology... ► Artikel lesen | |
| FRESENIUS | 46,860 | +0,69 % | +40 Prozent seit Jahresbeginn: Fresenius kehrt mit Milliarden-Anleihe zurück - Analysten empfehlen zum Kauf! | © Foto: Arne Dedert/dpaFresenius stärkt mit einer Milliarden-Anleihe seine Bilanz und Analysten sehen trotz Rallye weiteres Kurspotenzial für die Aktie.Der Gesundheitskonzern Fresenius ist mit einer... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 42,060 | -1,04 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 47,810 | +0,40 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen |
DEVYSER DIAGNOSTICS AB gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell +0,15 % bei einem Aktienkurs von 13,600 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DEVYSER DIAGNOSTICS AB finden Sie auf Wallstreet Online.